Drug-Induced Heart Failure (Part 1: The Urgency of the Problem, the Prevalence, the Effect of Certain Groups of Drugs on the Risk of Development/Progression Heart Failure)

Despite all the achievements of modern medicine, heart failure remains one of the most prevalent, severe and prognostically unfavorable conditions that requires close attention of the medical community. The diversity of the clinical picture and the large number of co-morbidities go hand in hand with a rather complicated pharmacotherapy regimen which, in the vast majority of cases, includes several medicines. Some classes of drugs can provoke the onset/progression of heart failure in patients with left ventricular dysfunction, as well as contribute to the development of heart failure in patients without concomitant cardiovascular diseases. The aim of the study was to analyse and systematise data on risk factors for the development of drug-induced heart failure and data on its prevalence when using various groups of medicines. It has been established that drug-induced heart failure typically develops in association with the use of calcium channel blockers (verapamil, diltiazem, nifedipine), beta-blockers (propranolol), antiarrhythmic drugs (disopyramide, dronedarone, lidocaine, lorcainide, mexiletine, moricizine, propafenone, tocainide, ﬂecainide, encainide), hypoglycemic drugs (rosiglitazone, pioglitazone, saxagliptin), anthracyclines (doxorubicin, epirubicin) and other anticancer drugs (bevacizumab, inﬂiximab, trastuzumab), and non-steroidal anti-inﬂ ammatory drugs (diclofenac, ibuprofen, celecoxib, rofecoxib). It is assumed that this pathology develops in a small number of patients, mainly those who already have left ventricular dysfunction. However, the effects of drugs should be considered as one of potential and preventable causes of heart failure development/progression. Raising clinicians’ awareness of the potential adverse effects of individual medicines or entire pharmacological classes of drugs on the cardiac function, especially in patients with left ventricle dysfunction, can facilitate the timely diagnosis and prevention of drug-induced heart failure. Ausführliche Beschreibung

Gespeichert in:

Autor*in:	O. D. Ostroumova [verfasserIn] I. V. Goloborodova [verfasserIn]

Format:	E-Artikel
Sprache:	Russisch

Erschienen:	2020

Schlagwörter:	heart failure drug-induced heart failure calcium channel blockers beta-blockers antiarrhythmics hypoglycemic drugs anthracyclines anticancer drugs non-steroidal anti-inﬂ ammatory drugs

Übergeordnetes Werk:	In: Безопасность и риск фармакотерапии - Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products», 2018, 8(2020), 1, Seite 23-35
Übergeordnetes Werk:	volume:8 ; year:2020 ; number:1 ; pages:23-35

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.30895/2312-7821-2020-8-1-23-35

Katalog-ID:	DOAJ004480295

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ004480295
003	DE-627
005	20240414040332.0
007	cr uuu---uuuuu
008	230225s2020 xx \|\|\|\|\|o 00\| \|\|rus c
024	7		\|a 10.30895/2312-7821-2020-8-1-23-35 \|2 doi
035			\|a (DE-627)DOAJ004480295
035			\|a (DE-599)DOAJ2ff0e0edd88142cdaa1c156de5e26774
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a rus
050		0	\|a RM1-950
100	0		\|a O. D. Ostroumova \|e verfasserin \|4 aut
245	1	0	\|a Drug-Induced Heart Failure (Part 1: The Urgency of the Problem, the Prevalence, the Effect of Certain Groups of Drugs on the Risk of Development/Progression Heart Failure)
264		1	\|c 2020
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Despite all the achievements of modern medicine, heart failure remains one of the most prevalent, severe and prognostically unfavorable conditions that requires close attention of the medical community. The diversity of the clinical picture and the large number of co-morbidities go hand in hand with a rather complicated pharmacotherapy regimen which, in the vast majority of cases, includes several medicines. Some classes of drugs can provoke the onset/progression of heart failure in patients with left ventricular dysfunction, as well as contribute to the development of heart failure in patients without concomitant cardiovascular diseases. The aim of the study was to analyse and systematise data on risk factors for the development of drug-induced heart failure and data on its prevalence when using various groups of medicines. It has been established that drug-induced heart failure typically develops in association with the use of calcium channel blockers (verapamil, diltiazem, nifedipine), beta-blockers (propranolol), antiarrhythmic drugs (disopyramide, dronedarone, lidocaine, lorcainide, mexiletine, moricizine, propafenone, tocainide, ﬂecainide, encainide), hypoglycemic drugs (rosiglitazone, pioglitazone, saxagliptin), anthracyclines (doxorubicin, epirubicin) and other anticancer drugs (bevacizumab, inﬂiximab, trastuzumab), and non-steroidal anti-inﬂ ammatory drugs (diclofenac, ibuprofen, celecoxib, rofecoxib). It is assumed that this pathology develops in a small number of patients, mainly those who already have left ventricular dysfunction. However, the effects of drugs should be considered as one of potential and preventable causes of heart failure development/progression. Raising clinicians’ awareness of the potential adverse effects of individual medicines or entire pharmacological classes of drugs on the cardiac function, especially in patients with left ventricle dysfunction, can facilitate the timely diagnosis and prevention of drug-induced heart failure.
650		4	\|a heart failure
650		4	\|a drug-induced heart failure
650		4	\|a calcium channel blockers
650		4	\|a beta-blockers
650		4	\|a antiarrhythmics
650		4	\|a hypoglycemic drugs
650		4	\|a anthracyclines
650		4	\|a anticancer drugs
650		4	\|a non-steroidal anti-inﬂ ammatory drugs
653		0	\|a Therapeutics. Pharmacology
700	0		\|a I. V. Goloborodova \|e verfasserin \|4 aut
773	0	8	\|i In \|t Безопасность и риск фармакотерапии \|d Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products», 2018 \|g 8(2020), 1, Seite 23-35 \|w (DE-627)1760649848 \|x 26191164 \|7 nnns
773	1	8	\|g volume:8 \|g year:2020 \|g number:1 \|g pages:23-35
856	4	0	\|u https://doi.org/10.30895/2312-7821-2020-8-1-23-35 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/2ff0e0edd88142cdaa1c156de5e26774 \|z kostenfrei
856	4	0	\|u https://www.risksafety.ru/jour/article/view/171 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2312-7821 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2619-1164 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
951			\|a AR
952			\|d 8 \|j 2020 \|e 1 \|h 23-35

Indexfelder

author_variant	o d o odo i v g ivg
matchkey_str	article:26191164:2020----::rgnuehatalrpr1hugnyfhpolmhpeaectefetfetigopodusnhrs
hierarchy_sort_str	2020
callnumber-subject-code	RM
publishDate	2020
allfields	10.30895/2312-7821-2020-8-1-23-35 doi (DE-627)DOAJ004480295 (DE-599)DOAJ2ff0e0edd88142cdaa1c156de5e26774 DE-627 ger DE-627 rakwb rus RM1-950 O. D. Ostroumova verfasserin aut Drug-Induced Heart Failure (Part 1: The Urgency of the Problem, the Prevalence, the Effect of Certain Groups of Drugs on the Risk of Development/Progression Heart Failure) 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Despite all the achievements of modern medicine, heart failure remains one of the most prevalent, severe and prognostically unfavorable conditions that requires close attention of the medical community. The diversity of the clinical picture and the large number of co-morbidities go hand in hand with a rather complicated pharmacotherapy regimen which, in the vast majority of cases, includes several medicines. Some classes of drugs can provoke the onset/progression of heart failure in patients with left ventricular dysfunction, as well as contribute to the development of heart failure in patients without concomitant cardiovascular diseases. The aim of the study was to analyse and systematise data on risk factors for the development of drug-induced heart failure and data on its prevalence when using various groups of medicines. It has been established that drug-induced heart failure typically develops in association with the use of calcium channel blockers (verapamil, diltiazem, nifedipine), beta-blockers (propranolol), antiarrhythmic drugs (disopyramide, dronedarone, lidocaine, lorcainide, mexiletine, moricizine, propafenone, tocainide, ﬂecainide, encainide), hypoglycemic drugs (rosiglitazone, pioglitazone, saxagliptin), anthracyclines (doxorubicin, epirubicin) and other anticancer drugs (bevacizumab, inﬂiximab, trastuzumab), and non-steroidal anti-inﬂ ammatory drugs (diclofenac, ibuprofen, celecoxib, rofecoxib). It is assumed that this pathology develops in a small number of patients, mainly those who already have left ventricular dysfunction. However, the effects of drugs should be considered as one of potential and preventable causes of heart failure development/progression. Raising clinicians’ awareness of the potential adverse effects of individual medicines or entire pharmacological classes of drugs on the cardiac function, especially in patients with left ventricle dysfunction, can facilitate the timely diagnosis and prevention of drug-induced heart failure. heart failure drug-induced heart failure calcium channel blockers beta-blockers antiarrhythmics hypoglycemic drugs anthracyclines anticancer drugs non-steroidal anti-inﬂ ammatory drugs Therapeutics. Pharmacology I. V. Goloborodova verfasserin aut In Безопасность и риск фармакотерапии Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products», 2018 8(2020), 1, Seite 23-35 (DE-627)1760649848 26191164 nnns volume:8 year:2020 number:1 pages:23-35 https://doi.org/10.30895/2312-7821-2020-8-1-23-35 kostenfrei https://doaj.org/article/2ff0e0edd88142cdaa1c156de5e26774 kostenfrei https://www.risksafety.ru/jour/article/view/171 kostenfrei https://doaj.org/toc/2312-7821 Journal toc kostenfrei https://doaj.org/toc/2619-1164 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 8 2020 1 23-35
spelling	10.30895/2312-7821-2020-8-1-23-35 doi (DE-627)DOAJ004480295 (DE-599)DOAJ2ff0e0edd88142cdaa1c156de5e26774 DE-627 ger DE-627 rakwb rus RM1-950 O. D. Ostroumova verfasserin aut Drug-Induced Heart Failure (Part 1: The Urgency of the Problem, the Prevalence, the Effect of Certain Groups of Drugs on the Risk of Development/Progression Heart Failure) 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Despite all the achievements of modern medicine, heart failure remains one of the most prevalent, severe and prognostically unfavorable conditions that requires close attention of the medical community. The diversity of the clinical picture and the large number of co-morbidities go hand in hand with a rather complicated pharmacotherapy regimen which, in the vast majority of cases, includes several medicines. Some classes of drugs can provoke the onset/progression of heart failure in patients with left ventricular dysfunction, as well as contribute to the development of heart failure in patients without concomitant cardiovascular diseases. The aim of the study was to analyse and systematise data on risk factors for the development of drug-induced heart failure and data on its prevalence when using various groups of medicines. It has been established that drug-induced heart failure typically develops in association with the use of calcium channel blockers (verapamil, diltiazem, nifedipine), beta-blockers (propranolol), antiarrhythmic drugs (disopyramide, dronedarone, lidocaine, lorcainide, mexiletine, moricizine, propafenone, tocainide, ﬂecainide, encainide), hypoglycemic drugs (rosiglitazone, pioglitazone, saxagliptin), anthracyclines (doxorubicin, epirubicin) and other anticancer drugs (bevacizumab, inﬂiximab, trastuzumab), and non-steroidal anti-inﬂ ammatory drugs (diclofenac, ibuprofen, celecoxib, rofecoxib). It is assumed that this pathology develops in a small number of patients, mainly those who already have left ventricular dysfunction. However, the effects of drugs should be considered as one of potential and preventable causes of heart failure development/progression. Raising clinicians’ awareness of the potential adverse effects of individual medicines or entire pharmacological classes of drugs on the cardiac function, especially in patients with left ventricle dysfunction, can facilitate the timely diagnosis and prevention of drug-induced heart failure. heart failure drug-induced heart failure calcium channel blockers beta-blockers antiarrhythmics hypoglycemic drugs anthracyclines anticancer drugs non-steroidal anti-inﬂ ammatory drugs Therapeutics. Pharmacology I. V. Goloborodova verfasserin aut In Безопасность и риск фармакотерапии Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products», 2018 8(2020), 1, Seite 23-35 (DE-627)1760649848 26191164 nnns volume:8 year:2020 number:1 pages:23-35 https://doi.org/10.30895/2312-7821-2020-8-1-23-35 kostenfrei https://doaj.org/article/2ff0e0edd88142cdaa1c156de5e26774 kostenfrei https://www.risksafety.ru/jour/article/view/171 kostenfrei https://doaj.org/toc/2312-7821 Journal toc kostenfrei https://doaj.org/toc/2619-1164 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 8 2020 1 23-35
allfields_unstemmed	10.30895/2312-7821-2020-8-1-23-35 doi (DE-627)DOAJ004480295 (DE-599)DOAJ2ff0e0edd88142cdaa1c156de5e26774 DE-627 ger DE-627 rakwb rus RM1-950 O. D. Ostroumova verfasserin aut Drug-Induced Heart Failure (Part 1: The Urgency of the Problem, the Prevalence, the Effect of Certain Groups of Drugs on the Risk of Development/Progression Heart Failure) 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Despite all the achievements of modern medicine, heart failure remains one of the most prevalent, severe and prognostically unfavorable conditions that requires close attention of the medical community. The diversity of the clinical picture and the large number of co-morbidities go hand in hand with a rather complicated pharmacotherapy regimen which, in the vast majority of cases, includes several medicines. Some classes of drugs can provoke the onset/progression of heart failure in patients with left ventricular dysfunction, as well as contribute to the development of heart failure in patients without concomitant cardiovascular diseases. The aim of the study was to analyse and systematise data on risk factors for the development of drug-induced heart failure and data on its prevalence when using various groups of medicines. It has been established that drug-induced heart failure typically develops in association with the use of calcium channel blockers (verapamil, diltiazem, nifedipine), beta-blockers (propranolol), antiarrhythmic drugs (disopyramide, dronedarone, lidocaine, lorcainide, mexiletine, moricizine, propafenone, tocainide, ﬂecainide, encainide), hypoglycemic drugs (rosiglitazone, pioglitazone, saxagliptin), anthracyclines (doxorubicin, epirubicin) and other anticancer drugs (bevacizumab, inﬂiximab, trastuzumab), and non-steroidal anti-inﬂ ammatory drugs (diclofenac, ibuprofen, celecoxib, rofecoxib). It is assumed that this pathology develops in a small number of patients, mainly those who already have left ventricular dysfunction. However, the effects of drugs should be considered as one of potential and preventable causes of heart failure development/progression. Raising clinicians’ awareness of the potential adverse effects of individual medicines or entire pharmacological classes of drugs on the cardiac function, especially in patients with left ventricle dysfunction, can facilitate the timely diagnosis and prevention of drug-induced heart failure. heart failure drug-induced heart failure calcium channel blockers beta-blockers antiarrhythmics hypoglycemic drugs anthracyclines anticancer drugs non-steroidal anti-inﬂ ammatory drugs Therapeutics. Pharmacology I. V. Goloborodova verfasserin aut In Безопасность и риск фармакотерапии Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products», 2018 8(2020), 1, Seite 23-35 (DE-627)1760649848 26191164 nnns volume:8 year:2020 number:1 pages:23-35 https://doi.org/10.30895/2312-7821-2020-8-1-23-35 kostenfrei https://doaj.org/article/2ff0e0edd88142cdaa1c156de5e26774 kostenfrei https://www.risksafety.ru/jour/article/view/171 kostenfrei https://doaj.org/toc/2312-7821 Journal toc kostenfrei https://doaj.org/toc/2619-1164 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 8 2020 1 23-35
allfieldsGer	10.30895/2312-7821-2020-8-1-23-35 doi (DE-627)DOAJ004480295 (DE-599)DOAJ2ff0e0edd88142cdaa1c156de5e26774 DE-627 ger DE-627 rakwb rus RM1-950 O. D. Ostroumova verfasserin aut Drug-Induced Heart Failure (Part 1: The Urgency of the Problem, the Prevalence, the Effect of Certain Groups of Drugs on the Risk of Development/Progression Heart Failure) 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Despite all the achievements of modern medicine, heart failure remains one of the most prevalent, severe and prognostically unfavorable conditions that requires close attention of the medical community. The diversity of the clinical picture and the large number of co-morbidities go hand in hand with a rather complicated pharmacotherapy regimen which, in the vast majority of cases, includes several medicines. Some classes of drugs can provoke the onset/progression of heart failure in patients with left ventricular dysfunction, as well as contribute to the development of heart failure in patients without concomitant cardiovascular diseases. The aim of the study was to analyse and systematise data on risk factors for the development of drug-induced heart failure and data on its prevalence when using various groups of medicines. It has been established that drug-induced heart failure typically develops in association with the use of calcium channel blockers (verapamil, diltiazem, nifedipine), beta-blockers (propranolol), antiarrhythmic drugs (disopyramide, dronedarone, lidocaine, lorcainide, mexiletine, moricizine, propafenone, tocainide, ﬂecainide, encainide), hypoglycemic drugs (rosiglitazone, pioglitazone, saxagliptin), anthracyclines (doxorubicin, epirubicin) and other anticancer drugs (bevacizumab, inﬂiximab, trastuzumab), and non-steroidal anti-inﬂ ammatory drugs (diclofenac, ibuprofen, celecoxib, rofecoxib). It is assumed that this pathology develops in a small number of patients, mainly those who already have left ventricular dysfunction. However, the effects of drugs should be considered as one of potential and preventable causes of heart failure development/progression. Raising clinicians’ awareness of the potential adverse effects of individual medicines or entire pharmacological classes of drugs on the cardiac function, especially in patients with left ventricle dysfunction, can facilitate the timely diagnosis and prevention of drug-induced heart failure. heart failure drug-induced heart failure calcium channel blockers beta-blockers antiarrhythmics hypoglycemic drugs anthracyclines anticancer drugs non-steroidal anti-inﬂ ammatory drugs Therapeutics. Pharmacology I. V. Goloborodova verfasserin aut In Безопасность и риск фармакотерапии Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products», 2018 8(2020), 1, Seite 23-35 (DE-627)1760649848 26191164 nnns volume:8 year:2020 number:1 pages:23-35 https://doi.org/10.30895/2312-7821-2020-8-1-23-35 kostenfrei https://doaj.org/article/2ff0e0edd88142cdaa1c156de5e26774 kostenfrei https://www.risksafety.ru/jour/article/view/171 kostenfrei https://doaj.org/toc/2312-7821 Journal toc kostenfrei https://doaj.org/toc/2619-1164 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 8 2020 1 23-35
allfieldsSound	10.30895/2312-7821-2020-8-1-23-35 doi (DE-627)DOAJ004480295 (DE-599)DOAJ2ff0e0edd88142cdaa1c156de5e26774 DE-627 ger DE-627 rakwb rus RM1-950 O. D. Ostroumova verfasserin aut Drug-Induced Heart Failure (Part 1: The Urgency of the Problem, the Prevalence, the Effect of Certain Groups of Drugs on the Risk of Development/Progression Heart Failure) 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Despite all the achievements of modern medicine, heart failure remains one of the most prevalent, severe and prognostically unfavorable conditions that requires close attention of the medical community. The diversity of the clinical picture and the large number of co-morbidities go hand in hand with a rather complicated pharmacotherapy regimen which, in the vast majority of cases, includes several medicines. Some classes of drugs can provoke the onset/progression of heart failure in patients with left ventricular dysfunction, as well as contribute to the development of heart failure in patients without concomitant cardiovascular diseases. The aim of the study was to analyse and systematise data on risk factors for the development of drug-induced heart failure and data on its prevalence when using various groups of medicines. It has been established that drug-induced heart failure typically develops in association with the use of calcium channel blockers (verapamil, diltiazem, nifedipine), beta-blockers (propranolol), antiarrhythmic drugs (disopyramide, dronedarone, lidocaine, lorcainide, mexiletine, moricizine, propafenone, tocainide, ﬂecainide, encainide), hypoglycemic drugs (rosiglitazone, pioglitazone, saxagliptin), anthracyclines (doxorubicin, epirubicin) and other anticancer drugs (bevacizumab, inﬂiximab, trastuzumab), and non-steroidal anti-inﬂ ammatory drugs (diclofenac, ibuprofen, celecoxib, rofecoxib). It is assumed that this pathology develops in a small number of patients, mainly those who already have left ventricular dysfunction. However, the effects of drugs should be considered as one of potential and preventable causes of heart failure development/progression. Raising clinicians’ awareness of the potential adverse effects of individual medicines or entire pharmacological classes of drugs on the cardiac function, especially in patients with left ventricle dysfunction, can facilitate the timely diagnosis and prevention of drug-induced heart failure. heart failure drug-induced heart failure calcium channel blockers beta-blockers antiarrhythmics hypoglycemic drugs anthracyclines anticancer drugs non-steroidal anti-inﬂ ammatory drugs Therapeutics. Pharmacology I. V. Goloborodova verfasserin aut In Безопасность и риск фармакотерапии Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products», 2018 8(2020), 1, Seite 23-35 (DE-627)1760649848 26191164 nnns volume:8 year:2020 number:1 pages:23-35 https://doi.org/10.30895/2312-7821-2020-8-1-23-35 kostenfrei https://doaj.org/article/2ff0e0edd88142cdaa1c156de5e26774 kostenfrei https://www.risksafety.ru/jour/article/view/171 kostenfrei https://doaj.org/toc/2312-7821 Journal toc kostenfrei https://doaj.org/toc/2619-1164 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 8 2020 1 23-35
language	Russian
source	In Безопасность и риск фармакотерапии 8(2020), 1, Seite 23-35 volume:8 year:2020 number:1 pages:23-35
sourceStr	In Безопасность и риск фармакотерапии 8(2020), 1, Seite 23-35 volume:8 year:2020 number:1 pages:23-35
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	heart failure drug-induced heart failure calcium channel blockers beta-blockers antiarrhythmics hypoglycemic drugs anthracyclines anticancer drugs non-steroidal anti-inﬂ ammatory drugs Therapeutics. Pharmacology
isfreeaccess_bool	true
container_title	Безопасность и риск фармакотерапии
authorswithroles_txt_mv	O. D. Ostroumova @@aut@@ I. V. Goloborodova @@aut@@
publishDateDaySort_date	2020-01-01T00:00:00Z
hierarchy_top_id	1760649848
id	DOAJ004480295
language_de	russisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ004480295</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414040332.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2020 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.30895/2312-7821-2020-8-1-23-35</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ004480295</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ2ff0e0edd88142cdaa1c156de5e26774</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">O. D. Ostroumova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Drug-Induced Heart Failure (Part 1: The Urgency of the Problem, the Prevalence, the Effect of Certain Groups of Drugs on the Risk of Development/Progression Heart Failure)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Despite all the achievements of modern medicine, heart failure remains one of the most prevalent, severe and prognostically unfavorable conditions that requires close attention of the medical community. The diversity of the clinical picture and the large number of co-morbidities go hand in hand with a rather complicated pharmacotherapy regimen which, in the vast majority of cases, includes several medicines. Some classes of drugs can provoke the onset/progression of heart failure in patients with left ventricular dysfunction, as well as contribute to the development of heart failure in patients without concomitant cardiovascular diseases. The aim of the study was to analyse and systematise data on risk factors for the development of drug-induced heart failure and data on its prevalence when using various groups of medicines. It has been established that drug-induced heart failure typically develops in association with the use of calcium channel blockers (verapamil, diltiazem, nifedipine), beta-blockers (propranolol), antiarrhythmic drugs (disopyramide, dronedarone, lidocaine, lorcainide, mexiletine, moricizine, propafenone, tocainide, ﬂecainide, encainide), hypoglycemic drugs (rosiglitazone, pioglitazone, saxagliptin), anthracyclines (doxorubicin, epirubicin) and other anticancer drugs (bevacizumab, inﬂiximab, trastuzumab), and non-steroidal anti-inﬂ ammatory drugs (diclofenac, ibuprofen, celecoxib, rofecoxib). It is assumed that this pathology develops in a small number of patients, mainly those who already have left ventricular dysfunction. However, the effects of drugs should be considered as one of potential and preventable causes of heart failure development/progression. Raising clinicians’ awareness of the potential adverse effects of individual medicines or entire pharmacological classes of drugs on the cardiac function, especially in patients with left ventricle dysfunction, can facilitate the timely diagnosis and prevention of drug-induced heart failure.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">heart failure</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">drug-induced heart failure</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">calcium channel blockers</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">beta-blockers</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">antiarrhythmics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hypoglycemic drugs</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">anthracyclines</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">anticancer drugs</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">non-steroidal anti-inﬂ ammatory drugs</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I. V. Goloborodova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Безопасность и риск фармакотерапии</subfield><subfield code="d">Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products», 2018</subfield><subfield code="g">8(2020), 1, Seite 23-35</subfield><subfield code="w">(DE-627)1760649848</subfield><subfield code="x">26191164</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:23-35</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.30895/2312-7821-2020-8-1-23-35</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/2ff0e0edd88142cdaa1c156de5e26774</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.risksafety.ru/jour/article/view/171</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2312-7821</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2619-1164</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2020</subfield><subfield code="e">1</subfield><subfield code="h">23-35</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	O. D. Ostroumova
spellingShingle	O. D. Ostroumova misc RM1-950 misc heart failure misc drug-induced heart failure misc calcium channel blockers misc beta-blockers misc antiarrhythmics misc hypoglycemic drugs misc anthracyclines misc anticancer drugs misc non-steroidal anti-inﬂ ammatory drugs misc Therapeutics. Pharmacology Drug-Induced Heart Failure (Part 1: The Urgency of the Problem, the Prevalence, the Effect of Certain Groups of Drugs on the Risk of Development/Progression Heart Failure)
authorStr	O. D. Ostroumova
ppnlink_with_tag_str_mv	@@773@@(DE-627)1760649848
format	electronic Article
delete_txt_mv	keep
author_role	aut aut
collection	DOAJ
remote_str	true
callnumber-label	RM1-950
illustrated	Not Illustrated
issn	26191164
topic_title	RM1-950 Drug-Induced Heart Failure (Part 1: The Urgency of the Problem, the Prevalence, the Effect of Certain Groups of Drugs on the Risk of Development/Progression Heart Failure) heart failure drug-induced heart failure calcium channel blockers beta-blockers antiarrhythmics hypoglycemic drugs anthracyclines anticancer drugs non-steroidal anti-inﬂ ammatory drugs
topic	misc RM1-950 misc heart failure misc drug-induced heart failure misc calcium channel blockers misc beta-blockers misc antiarrhythmics misc hypoglycemic drugs misc anthracyclines misc anticancer drugs misc non-steroidal anti-inﬂ ammatory drugs misc Therapeutics. Pharmacology
topic_unstemmed	misc RM1-950 misc heart failure misc drug-induced heart failure misc calcium channel blockers misc beta-blockers misc antiarrhythmics misc hypoglycemic drugs misc anthracyclines misc anticancer drugs misc non-steroidal anti-inﬂ ammatory drugs misc Therapeutics. Pharmacology
topic_browse	misc RM1-950 misc heart failure misc drug-induced heart failure misc calcium channel blockers misc beta-blockers misc antiarrhythmics misc hypoglycemic drugs misc anthracyclines misc anticancer drugs misc non-steroidal anti-inﬂ ammatory drugs misc Therapeutics. Pharmacology
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Безопасность и риск фармакотерапии
hierarchy_parent_id	1760649848
hierarchy_top_title	Безопасность и риск фармакотерапии
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1760649848
title	Drug-Induced Heart Failure (Part 1: The Urgency of the Problem, the Prevalence, the Effect of Certain Groups of Drugs on the Risk of Development/Progression Heart Failure)
ctrlnum	(DE-627)DOAJ004480295 (DE-599)DOAJ2ff0e0edd88142cdaa1c156de5e26774
title_full	Drug-Induced Heart Failure (Part 1: The Urgency of the Problem, the Prevalence, the Effect of Certain Groups of Drugs on the Risk of Development/Progression Heart Failure)
author_sort	O. D. Ostroumova
journal	Безопасность и риск фармакотерапии
journalStr	Безопасность и риск фармакотерапии
callnumber-first-code	R
lang_code	rus
isOA_bool	true
recordtype	marc
publishDateSort	2020
contenttype_str_mv	txt
container_start_page	23
author_browse	O. D. Ostroumova I. V. Goloborodova
container_volume	8
class	RM1-950
format_se	Elektronische Aufsätze
author-letter	O. D. Ostroumova
doi_str_mv	10.30895/2312-7821-2020-8-1-23-35
author2-role	verfasserin
title_sort	drug-induced heart failure (part 1: the urgency of the problem, the prevalence, the effect of certain groups of drugs on the risk of development/progression heart failure)
callnumber	RM1-950
title_auth	Drug-Induced Heart Failure (Part 1: The Urgency of the Problem, the Prevalence, the Effect of Certain Groups of Drugs on the Risk of Development/Progression Heart Failure)
abstract	Despite all the achievements of modern medicine, heart failure remains one of the most prevalent, severe and prognostically unfavorable conditions that requires close attention of the medical community. The diversity of the clinical picture and the large number of co-morbidities go hand in hand with a rather complicated pharmacotherapy regimen which, in the vast majority of cases, includes several medicines. Some classes of drugs can provoke the onset/progression of heart failure in patients with left ventricular dysfunction, as well as contribute to the development of heart failure in patients without concomitant cardiovascular diseases. The aim of the study was to analyse and systematise data on risk factors for the development of drug-induced heart failure and data on its prevalence when using various groups of medicines. It has been established that drug-induced heart failure typically develops in association with the use of calcium channel blockers (verapamil, diltiazem, nifedipine), beta-blockers (propranolol), antiarrhythmic drugs (disopyramide, dronedarone, lidocaine, lorcainide, mexiletine, moricizine, propafenone, tocainide, ﬂecainide, encainide), hypoglycemic drugs (rosiglitazone, pioglitazone, saxagliptin), anthracyclines (doxorubicin, epirubicin) and other anticancer drugs (bevacizumab, inﬂiximab, trastuzumab), and non-steroidal anti-inﬂ ammatory drugs (diclofenac, ibuprofen, celecoxib, rofecoxib). It is assumed that this pathology develops in a small number of patients, mainly those who already have left ventricular dysfunction. However, the effects of drugs should be considered as one of potential and preventable causes of heart failure development/progression. Raising clinicians’ awareness of the potential adverse effects of individual medicines or entire pharmacological classes of drugs on the cardiac function, especially in patients with left ventricle dysfunction, can facilitate the timely diagnosis and prevention of drug-induced heart failure.
abstractGer	Despite all the achievements of modern medicine, heart failure remains one of the most prevalent, severe and prognostically unfavorable conditions that requires close attention of the medical community. The diversity of the clinical picture and the large number of co-morbidities go hand in hand with a rather complicated pharmacotherapy regimen which, in the vast majority of cases, includes several medicines. Some classes of drugs can provoke the onset/progression of heart failure in patients with left ventricular dysfunction, as well as contribute to the development of heart failure in patients without concomitant cardiovascular diseases. The aim of the study was to analyse and systematise data on risk factors for the development of drug-induced heart failure and data on its prevalence when using various groups of medicines. It has been established that drug-induced heart failure typically develops in association with the use of calcium channel blockers (verapamil, diltiazem, nifedipine), beta-blockers (propranolol), antiarrhythmic drugs (disopyramide, dronedarone, lidocaine, lorcainide, mexiletine, moricizine, propafenone, tocainide, ﬂecainide, encainide), hypoglycemic drugs (rosiglitazone, pioglitazone, saxagliptin), anthracyclines (doxorubicin, epirubicin) and other anticancer drugs (bevacizumab, inﬂiximab, trastuzumab), and non-steroidal anti-inﬂ ammatory drugs (diclofenac, ibuprofen, celecoxib, rofecoxib). It is assumed that this pathology develops in a small number of patients, mainly those who already have left ventricular dysfunction. However, the effects of drugs should be considered as one of potential and preventable causes of heart failure development/progression. Raising clinicians’ awareness of the potential adverse effects of individual medicines or entire pharmacological classes of drugs on the cardiac function, especially in patients with left ventricle dysfunction, can facilitate the timely diagnosis and prevention of drug-induced heart failure.
abstract_unstemmed	Despite all the achievements of modern medicine, heart failure remains one of the most prevalent, severe and prognostically unfavorable conditions that requires close attention of the medical community. The diversity of the clinical picture and the large number of co-morbidities go hand in hand with a rather complicated pharmacotherapy regimen which, in the vast majority of cases, includes several medicines. Some classes of drugs can provoke the onset/progression of heart failure in patients with left ventricular dysfunction, as well as contribute to the development of heart failure in patients without concomitant cardiovascular diseases. The aim of the study was to analyse and systematise data on risk factors for the development of drug-induced heart failure and data on its prevalence when using various groups of medicines. It has been established that drug-induced heart failure typically develops in association with the use of calcium channel blockers (verapamil, diltiazem, nifedipine), beta-blockers (propranolol), antiarrhythmic drugs (disopyramide, dronedarone, lidocaine, lorcainide, mexiletine, moricizine, propafenone, tocainide, ﬂecainide, encainide), hypoglycemic drugs (rosiglitazone, pioglitazone, saxagliptin), anthracyclines (doxorubicin, epirubicin) and other anticancer drugs (bevacizumab, inﬂiximab, trastuzumab), and non-steroidal anti-inﬂ ammatory drugs (diclofenac, ibuprofen, celecoxib, rofecoxib). It is assumed that this pathology develops in a small number of patients, mainly those who already have left ventricular dysfunction. However, the effects of drugs should be considered as one of potential and preventable causes of heart failure development/progression. Raising clinicians’ awareness of the potential adverse effects of individual medicines or entire pharmacological classes of drugs on the cardiac function, especially in patients with left ventricle dysfunction, can facilitate the timely diagnosis and prevention of drug-induced heart failure.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ
container_issue	1
title_short	Drug-Induced Heart Failure (Part 1: The Urgency of the Problem, the Prevalence, the Effect of Certain Groups of Drugs on the Risk of Development/Progression Heart Failure)
url	https://doi.org/10.30895/2312-7821-2020-8-1-23-35 https://doaj.org/article/2ff0e0edd88142cdaa1c156de5e26774 https://www.risksafety.ru/jour/article/view/171 https://doaj.org/toc/2312-7821 https://doaj.org/toc/2619-1164
remote_bool	true
author2	I. V. Goloborodova
author2Str	I. V. Goloborodova
ppnlink	1760649848
callnumber-subject	RM - Therapeutics and Pharmacology
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.30895/2312-7821-2020-8-1-23-35
callnumber-a	RM1-950
up_date	2024-07-03T23:54:27.842Z
_version_	1803604058799341568
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ004480295</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414040332.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2020 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.30895/2312-7821-2020-8-1-23-35</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ004480295</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ2ff0e0edd88142cdaa1c156de5e26774</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">O. D. Ostroumova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Drug-Induced Heart Failure (Part 1: The Urgency of the Problem, the Prevalence, the Effect of Certain Groups of Drugs on the Risk of Development/Progression Heart Failure)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Despite all the achievements of modern medicine, heart failure remains one of the most prevalent, severe and prognostically unfavorable conditions that requires close attention of the medical community. The diversity of the clinical picture and the large number of co-morbidities go hand in hand with a rather complicated pharmacotherapy regimen which, in the vast majority of cases, includes several medicines. Some classes of drugs can provoke the onset/progression of heart failure in patients with left ventricular dysfunction, as well as contribute to the development of heart failure in patients without concomitant cardiovascular diseases. The aim of the study was to analyse and systematise data on risk factors for the development of drug-induced heart failure and data on its prevalence when using various groups of medicines. It has been established that drug-induced heart failure typically develops in association with the use of calcium channel blockers (verapamil, diltiazem, nifedipine), beta-blockers (propranolol), antiarrhythmic drugs (disopyramide, dronedarone, lidocaine, lorcainide, mexiletine, moricizine, propafenone, tocainide, ﬂecainide, encainide), hypoglycemic drugs (rosiglitazone, pioglitazone, saxagliptin), anthracyclines (doxorubicin, epirubicin) and other anticancer drugs (bevacizumab, inﬂiximab, trastuzumab), and non-steroidal anti-inﬂ ammatory drugs (diclofenac, ibuprofen, celecoxib, rofecoxib). It is assumed that this pathology develops in a small number of patients, mainly those who already have left ventricular dysfunction. However, the effects of drugs should be considered as one of potential and preventable causes of heart failure development/progression. Raising clinicians’ awareness of the potential adverse effects of individual medicines or entire pharmacological classes of drugs on the cardiac function, especially in patients with left ventricle dysfunction, can facilitate the timely diagnosis and prevention of drug-induced heart failure.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">heart failure</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">drug-induced heart failure</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">calcium channel blockers</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">beta-blockers</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">antiarrhythmics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hypoglycemic drugs</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">anthracyclines</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">anticancer drugs</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">non-steroidal anti-inﬂ ammatory drugs</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I. V. Goloborodova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Безопасность и риск фармакотерапии</subfield><subfield code="d">Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products», 2018</subfield><subfield code="g">8(2020), 1, Seite 23-35</subfield><subfield code="w">(DE-627)1760649848</subfield><subfield code="x">26191164</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:23-35</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.30895/2312-7821-2020-8-1-23-35</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/2ff0e0edd88142cdaa1c156de5e26774</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.risksafety.ru/jour/article/view/171</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2312-7821</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2619-1164</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2020</subfield><subfield code="e">1</subfield><subfield code="h">23-35</subfield></datafield></record></collection>
score	7.400923

Nicht das Richtige dabei?

Schreiben Sie uns!

Drug-Induced Heart Failure (Part 1: The Urgency of the Problem, the Prevalence, the Effect of Certain Groups of Drugs on the Risk of Development/Progression Heart Failure)

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?